Abstract
Ketogenic diet is an established and effective non-pharmacologic treatment for drug-resistant epilepsy. Ketogenic diet represents the treatment of choice for GLUT-1 deficiency syndrome and pyruvate dehydrogenase complex deficiency. Infantile spasms, Dravet syndrome and myoclonic-astatic epilepsy are epilepsy syndromes for which ketogenic diet should be considered early in the therapeutic pathway. Recently, clinical indications for ketogenic diet have been increasing, as there is emerging evidence regarding safety and effectiveness. Specifically, ketogenic diet response has been investigated in refractory status epilepticus and encephalopathy with status epilepticus during sleep. New targets in neuropharmacology, such as mitochondrial permeability transition, are being studied and might lead to using it effectively in other neurological diseases. But, inefficient connectivity and impaired ketogenic diet proposal limit ideal availability of this therapeutic option. Ketogenic diet in Italy is not yet considered as standard of care, not even as a therapeutic option for many child neurologists and epileptologists. Conclusions: The aim of this review is to revisit ketogenic diet effectiveness and safety in order to highlight its importance in drug-resistant epilepsy and other neurological disorders.(Table presented.)
| Original language | English |
|---|---|
| Pages (from-to) | 1-10 |
| Number of pages | 10 |
| Journal | European Journal of Pediatrics |
| DOIs | |
| Publication status | Accepted/In press - Sep 1 2016 |
Fingerprint
Keywords
- Dietary therapy
- Drug-resistant epilepsy
- GLUT1DS ketones
- Ketogenic diet
- Modified Atkins diet
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
Cite this
The changing face of dietary therapy for epilepsy. / Pasca, Ludovica; de Giorgis, Valentina; Macasaet, Joyce Ann; Trentani, Claudia; Tagliabue, Anna; Veggiotti, Pierangelo.
In: European Journal of Pediatrics, 01.09.2016, p. 1-10.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The changing face of dietary therapy for epilepsy
AU - Pasca, Ludovica
AU - de Giorgis, Valentina
AU - Macasaet, Joyce Ann
AU - Trentani, Claudia
AU - Tagliabue, Anna
AU - Veggiotti, Pierangelo
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Ketogenic diet is an established and effective non-pharmacologic treatment for drug-resistant epilepsy. Ketogenic diet represents the treatment of choice for GLUT-1 deficiency syndrome and pyruvate dehydrogenase complex deficiency. Infantile spasms, Dravet syndrome and myoclonic-astatic epilepsy are epilepsy syndromes for which ketogenic diet should be considered early in the therapeutic pathway. Recently, clinical indications for ketogenic diet have been increasing, as there is emerging evidence regarding safety and effectiveness. Specifically, ketogenic diet response has been investigated in refractory status epilepticus and encephalopathy with status epilepticus during sleep. New targets in neuropharmacology, such as mitochondrial permeability transition, are being studied and might lead to using it effectively in other neurological diseases. But, inefficient connectivity and impaired ketogenic diet proposal limit ideal availability of this therapeutic option. Ketogenic diet in Italy is not yet considered as standard of care, not even as a therapeutic option for many child neurologists and epileptologists. Conclusions: The aim of this review is to revisit ketogenic diet effectiveness and safety in order to highlight its importance in drug-resistant epilepsy and other neurological disorders.(Table presented.)
AB - Ketogenic diet is an established and effective non-pharmacologic treatment for drug-resistant epilepsy. Ketogenic diet represents the treatment of choice for GLUT-1 deficiency syndrome and pyruvate dehydrogenase complex deficiency. Infantile spasms, Dravet syndrome and myoclonic-astatic epilepsy are epilepsy syndromes for which ketogenic diet should be considered early in the therapeutic pathway. Recently, clinical indications for ketogenic diet have been increasing, as there is emerging evidence regarding safety and effectiveness. Specifically, ketogenic diet response has been investigated in refractory status epilepticus and encephalopathy with status epilepticus during sleep. New targets in neuropharmacology, such as mitochondrial permeability transition, are being studied and might lead to using it effectively in other neurological diseases. But, inefficient connectivity and impaired ketogenic diet proposal limit ideal availability of this therapeutic option. Ketogenic diet in Italy is not yet considered as standard of care, not even as a therapeutic option for many child neurologists and epileptologists. Conclusions: The aim of this review is to revisit ketogenic diet effectiveness and safety in order to highlight its importance in drug-resistant epilepsy and other neurological disorders.(Table presented.)
KW - Dietary therapy
KW - Drug-resistant epilepsy
KW - GLUT1DS ketones
KW - Ketogenic diet
KW - Modified Atkins diet
UR - http://www.scopus.com/inward/record.url?scp=84984856679&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84984856679&partnerID=8YFLogxK
U2 - 10.1007/s00431-016-2765-z
DO - 10.1007/s00431-016-2765-z
M3 - Article
AN - SCOPUS:84984856679
SP - 1
EP - 10
JO - European Journal of Pediatrics
JF - European Journal of Pediatrics
SN - 0340-6199
ER -